← Oncology Approval Tracker

FDA DECISION ·

Mvasi + chemotherapy

bevacizumab-awwb with indication-specific chemotherapy · Amgen

FDA approvalNew or expanded indicationOvarian, fallopian tube and primary peritoneal cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adds labeled chemotherapy combinations for stage III or IV epithelial ovarian, fallopian tube or primary peritoneal cancer after initial surgery, for platinum-sensitive recurrence and for platinum-resistant recurrence after no more than two prior chemotherapy regimens.

LAMPGEN ANALYSIS

Why it matters

This supplemental biosimilar action expands use across three distinct ovarian cancer treatment settings.

What research teams should watch

Use the label to confirm combination and maintenance schedules based on recurrence and platinum history.

PRIMARY RECORDS

Sources